Life Sciences
Top stories summarized by our editors
11/19/2018

MorphoSys and I-Mab Biopharma have signed a deal to develop the anti-C5aR antibody cancer candidate MOR210. The agreement gives I-Mab exclusive regional development and licensing rights in Hong Kong, Macau, Taiwan and mainland China as well as South Korea, while MorphoSys gets an upfront payment of $3.5 million and is eligible for up to $101.5 million in milestones and royalties on net sales.

Full Story:
Seeking Alpha
More Summaries:
MorphoSys, I-Mab Biopharma
11/19/2018

Several chief scientific advisers to the European Commission asked the commission to revise the current directive on biotech crops to include gene-edited products. "There is a need to improve EU [biotech] legislation to be clear, evidence-based, implementable, proportionate and flexible enough to cope with future advances in science and technology in this area," the advisers said, arguing that biotech crops are likely safer than those produced from random mutagenesis.

More Summaries:
European Commission
11/19/2018

A team of researchers from Korea University and Georgia Tech developed a cotton fiber-based, glucose-powered biofuel cell to provide continuous power for implantable medical devices. The team reported in Nature Communications that the fuel cell converts chemical energy from glucose in the body into electrical energy through gold nanoparticles assembled on cotton fiber -- a process that improves the fuel cell's efficiency.

Full Story:
Engadget
11/19/2018

TIAA Bank has paid an undisclosed amount for a $1.5 billion health care equipment finance portfolio, including leases and loans to thousands of US health care providers, from General Electric's lending arm, GE Capital.

Full Story:
Reuters
11/19/2018

CareDx has raised $52.8 million in net proceeds from a public offering of 2.3 million shares of its common stock. The company will use the money as working capital, for general corporate functions and to potentially repay outstanding indebtedness under a credit deal with Perceptive Credit Holdings.

11/19/2018

Verily Life Sciences, a division of Alphabet, and Alcon have paused a four-year project to develop a smart contact lens for glucose monitoring in patients with diabetes. The companies are continuing with projects to develop smart lenses for presbyopia and to improve sight after cataract surgery.

Full Story:
Reuters
11/19/2018

Three-year data from a registry study of 800 patients with complex aortic abdominal aneurysm anatomy show use of Medtronic's Heli-FX EndoAnchor system prophylactically or after a failed endovascular repair or therapeutic revision was associated with low rates of Type Ia endoleaks. Patients also had high rates of freedom from secondary procedures and from aneurysm-related mortality.

Full Story:
MassDevice (Boston)
11/19/2018

A recent meeting of the FDA's Patient Engagement Advisory Committee convened by the agency's Center for Devices and Radiological Health covered the potential use of social media and other patient-generated data as a source of post-market medical device data. Panelists and speakers noted use of such information has benefits, such as reduced expense, easier patient follow-up and quicker FDA reaction to adverse events, but it brings several challenges, including privacy, accuracy and generalizability.

11/19/2018

Gilead's drug Vemlidy for chronic hepatitis B has been approved by the China National Medical Products Administration. The drug was approved as a once-daily treatment for those 12 and older.

Full Story:
BioSpectrum Asia
11/16/2018

The percentage of US adults with diabetes rose from 10.8% in 2008 to 2009 to 11.5% in 2016 to 2017, while obesity rates increased from 26.0% to 28.3%, according to the Gallup-Sharecare Well-Being Index. West Virginia had the highest diabetes rate at 17.9%, compared with less than 9% in Alaska, Colorado and Montana.

More Summaries:
diabetes